共 37 条
New insulin types in type 1 diabetes mellitus
被引:5
作者:
Mesa, Jordi
[1
]
机构:
[1] Hosp Univ Vall dHebron, Serv Endocrinol & Nutr, Barcelona, Spain
来源:
MEDICINA CLINICA
|
2015年
/
145卷
/
02期
关键词:
Diabetes mellitus;
Basal insulin;
Insulin analogue;
Insulin degludec;
Insulin glargine;
ACTING BASAL INSULIN;
GLARGINE U300 FORMULATION;
HYPOGLYCEMIA RISK;
EUGLYCEMIC CLAMP;
GLYCEMIC CONTROL;
BOLUS TREATMENT;
OPEN-LABEL;
DEGLUDEC;
LY2605541;
VARIABILITY;
D O I:
10.1016/j.medcli.2014.04.024
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Since its discovery almost a century ago, insulin remains the mainstay of treatment of patients with type 1 diabetes mellitus. Although progress in the synthesis of new formulations has been remarkable, the physiological profile of insulin is still different from that observed with preparations available nowadays. In the last decade, the introduction into clinical practice of insulin analogues has allowed significantly improvement in glycemic control and has facilitated the spread of basal/bolus patterns, the most physiological ones until now. Despite the benefits of basal analogues, glycemia often varies considerably when used as a single daily injection and this is why new molecules have been further investigated. Improvement has been achieved especially in terms of duration and rate of hypoglycemia, the main limiting factor of intensive therapy. This article reviews the available data concerning the new basal insulin analogues, degludec, pegylated lispro and glargine U300, and new formulations currently under development. (C) 2014 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:70 / 75
页数:6
相关论文